Two down and one to go. Merck just won summary judgment in one of the three closely watched Fosamax liability suits. It's the second Fosamax case......
Recommended Sources
Recommended Publications
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.
Web Buzz:
-
Merck Wins Dismissal Of Second Fosamax Trial
Pharmalot - 77 days 15 hours 17 minutes ago
This was to have been the second bellwether case against the drugmaker, which has been accused in some 1,000 lawsuits of failing to warn docs and...
Links from the Web Buzz:
- Amgen Gets More Good Data with Bone Drug Prolia, but Other Risks Await
- Botox Curbs Emotions, Study Says ... and Now Allergan Is Marketing It to Men
- New York Bills Would Mandate HPV Vaccines Without Parents' Consent
- Lilly CEO Tightens His Belt: Getting By on $21M a Year; Private Jet Off Limits for Personal Use
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs
- BMS's "Information Security Department" Has Spyware for Employee Laptops
- Pfizer's Little Tax Problem: $2B Bill Looms in 2011
- SEC Probe Into Dendreon Cancer Drug "Conspiracy" Could Put Rumors to Rest
- Analyst Rips Pfizer a New One Over $1.5B Guidance Discrepancy
- The Botox/Breast Implant Recession Is Over: Allergan, Others See Sales Up
- Conspiracy Theory About Dendreon's New Cancer Drug Could Soon Unravel
- Friday Biotech Funnies: Hitler's Peer Review Angst and Biotech's Id
- UPDATE: Paranoia Sweeps GSK Sales Reps Over Management "Spyware" on Laptops
- Wall Street Unleashes Fury at Pfizer's $1.5B Revenue Discrepancy
- GSK Earnings: $900M Spent on Lawyers; Silence on Job Cuts
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- Crazy Question: What If Sequenom's Down Syndrome Test Doesn't Exist?
- Acorda Therapeutic's MS Drug Ampyra Could Stumble
- If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Conspiracy Theory About Dendreon's New Cancer Drug Could Soon Unravel
- The Shame of the Lancet's Shoddy Autism Study Retraction
- Dendreon's New Stock Offering Takes Advantage of Provenge Decision Uncertainty
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- Efficacy of Roche's Flu Drug Tamiflu In Doubt
- The 5 Worst Drug Companies of 2009
- Why J&J's Stelara Launch Should Target Dermatologists First
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
Industry Transcripts by Seeking Alpha
- Biogen Idec, Inc. Q4 2009 Earnings Call Transcript
- Charles River Laboratories International Inc. Q4 2009 Earnings Call Transcript
- Ligand Pharmaceuticals Incorporated Q4 2009 Earnings Call Transcript
- Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcript
- Alkermes, Inc. F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
Brought to you by CBS MoneyWatch.com
- Best- and Worst-Paid College Degrees
- 6 Things You Should Never Do on Twitter or Facebook
- How Much Sleep Do You Really Need?
- 6 Big Myths about Gas Mileage
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
BNET User Analysis